#ECTRIMS2016 – Oryzon to Present Positive Preclinical Data on Potential MS Therapy

Researchers from Oryzon will present efficacy data on the company’s oral epigenetic drug ORY-2001, a potential treatment for multiple sclerosis (MS), at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress taking place this week in London. The poster presentation, “LSD1 inhibition, a potential epigenetic therapeutic approach for the…

Antioxidant Therapies Seen as Promising Approach in Treating MS and Like Diseases

A review article published in the British Journal of Pharmacology assesses antioxidant approaches for treating neurodegenerative disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The review, “Microglia antioxidant systems and redox signalling,” notes that certain compounds associated with oxidative stress appear to be promising…

MS Patients and Doctors Have a New Way of Working Together

A new partnership between ARM and HeartToHeart Networks LLC has brought healthcare providers of patients with neurodegenerative disorders, such as multiple sclerosis, a new and secure tool for remote health management. The novel health management (RHM) solution combines technology from both companies. It uses mobile devices adapted with a Trusted…